Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

The future of B cell-targeted therapies in Sjögren's syndrome.

Cornec D, Saraux A, Devauchelle-Pensec V, Clodic C, Pers JO.

Immunotherapy. 2013 Jun;5(6):639-46. doi: 10.2217/imt.13.49. Review.

PMID:
23725286
2.

B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.

Cornec D, Devauchelle-Pensec V, Tobón GJ, Pers JO, Jousse-Joulin S, Saraux A.

J Autoimmun. 2012 Sep;39(3):161-7. doi: 10.1016/j.jaut.2012.05.014. Epub 2012 Jun 30. Review.

PMID:
22749831
3.

B cell-targeted therapies in Sjögren's syndrome.

Tobón GJ, Pers JO, Youinou P, Saraux A.

Autoimmun Rev. 2010 Feb;9(4):224-8. doi: 10.1016/j.autrev.2009.08.001. Epub 2009 Aug 9. Review.

PMID:
19671451
4.

Anti-CD20 antibody in primary Sjögren's syndrome management.

Chen S, Liu Y, Shi G.

Curr Pharm Biotechnol. 2014;15(6):535-41. Review.

PMID:
25213362
5.

Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.

Coca A, Sanz I.

Curr Opin Rheumatol. 2012 Sep;24(5):451-6. doi: 10.1097/BOR.0b013e32835707e4. Review.

PMID:
22871954
6.

Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.

Abdulahad WH, Kroese FG, Vissink A, Bootsma H.

J Autoimmun. 2012 Aug;39(1-2):103-11. doi: 10.1016/j.jaut.2012.01.009. Epub 2012 Feb 15. Review.

PMID:
22341852
7.

Rituximab therapy in primary Sjögren's syndrome.

Alcântara C, Gomes MJ, Ferreira C.

Ann N Y Acad Sci. 2009 Sep;1173:701-5. doi: 10.1111/j.1749-6632.2009.04639.x.

PMID:
19758218
8.

Biologic treatments in Sjögren's syndrome.

Bowman S, Barone F.

Presse Med. 2012 Sep;41(9 Pt 2):e495-509. doi: 10.1016/j.lpm.2012.05.024. Epub 2012 Jul 24. Review.

PMID:
22836195
9.

Anti-B cell antibody therapies for inflammatory rheumatic diseases.

Faurschou M, Jayne DR.

Annu Rev Med. 2014;65:263-78. doi: 10.1146/annurev-med-070912-133235. Epub 2013 Oct 18. Review.

PMID:
24160940
10.

Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.

Hansen A, Lipsky PE, Dörner T.

Curr Opin Rheumatol. 2005 Sep;17(5):558-65. Review.

PMID:
16093833
11.

Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?

Meiners PM, Vissink A, Kallenberg CG, Kroese FG, Bootsma H.

Expert Opin Biol Ther. 2011 Oct;11(10):1381-94. doi: 10.1517/14712598.2011.605352. Epub 2011 Aug 7. Review.

PMID:
21819314
12.

Emerging biotherapies for Sjögren's syndrome.

Tobón GJ, Saraux A, Pers JO, Youinou P.

Expert Opin Emerg Drugs. 2010 Jun;15(2):269-82. doi: 10.1517/14728211003702392. Review.

PMID:
20384543
13.

B cell depletion in lupus and Sjögren's syndrome: an update.

Coca A, Sanz I.

Curr Opin Rheumatol. 2009 Sep;21(5):483-8. doi: 10.1097/BOR.0b013e32832efe55. Review.

PMID:
19644378
14.
15.

B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.

Hayakawa I, Tedder TF, Zhuang Y.

Immunology. 2007 Sep;122(1):73-9. Epub 2007 Apr 30.

16.

[B lymphocytes in Sjögren's syndrome].

Pers JO, Le Pottier L, Devauchelle V, Saraux A, Youinou P.

Rev Med Interne. 2008 Dec;29(12):1000-6. doi: 10.1016/j.revmed.2008.01.018. Epub 2008 Apr 10. Review. French.

PMID:
18403061
17.

B-cell populations and sub-populations in Sjögren's syndrome.

Hamza N, Bos NA, Kallenberg CG.

Presse Med. 2012 Sep;41(9 Pt 2):e475-83. doi: 10.1016/j.lpm.2012.05.021. Epub 2012 Jul 26. Review.

PMID:
22841377
18.

The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.

Saraux A.

Autoimmun Rev. 2010 Jul;9(9):609-14. doi: 10.1016/j.autrev.2010.05.007. Epub 2010 May 7. Review.

PMID:
20452466
19.

Therapeutic potential for B-cell modulation in Sjögren's syndrome.

Mariette X.

Rheum Dis Clin North Am. 2008 Nov;34(4):1025-33, x. doi: 10.1016/j.rdc.2008.08.014. Review.

PMID:
18984420
20.

Primary Sjögren's syndrome: pathophysiological, clinical and therapeutic advances.

Gottenberg JE.

Joint Bone Spine. 2009 Dec;76(6):591-4. doi: 10.1016/j.jbspin.2009.09.006.

PMID:
19932634

Supplemental Content

Support Center